FACULTY CO-CHAIRS

 

PATIENT

Luis Carale

PROGRAM DESCRIPTION

This activity will bring together multidisciplinary expert clinicians, as well as a patient with type 1 diabetes (T1D), in order to overview opportunities for the practical application of T1D screening and to intervene early with disease modifying therapies. In conversation with the faculty, the T1D patient will highlight their experience with T1D screening, what came next post-screening, as well as their journey to getting treatment to delay T1D progression. In addition, concise didactic presentations from faculty will be included to emphasize key concepts along this continuum of care in T1D.

TARGET AUDIENCE

This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D is needed, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals. Additionally, accessible programming and tools will be designed for patients, relatives, and members of the general population. As discussed within program descriptions, activities will be designed in a manner that allows learners to choose programming most relevant to their professional needs.

LEARNING OBJECTIVES

• Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring.
• Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions.
• Develop strategies for establishing referral pathways and enhancing collaboration with specialists in order to enable earlier application of disease-modifying therapies for early stage T1D.
• Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtual activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 CPEU.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Kimber Simmons, MD, MS	Consulting fees:	Sanofi, Shoreline Biosciences
	Contracted Research:	Sanofi
Kim Pfotenhauer DO, FACOFP, DABOM	Consulting fees:	Novo Nordisk
	Ownership Interest:	ROM Tech

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.

Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.

Shannon Mutch MS, RN, OCN has nothing to disclose.

A medical reviewer from CME Peer Review LLC, has nothing to disclose.

Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.

Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.

Melissa A. Johnson, Program Director for Med Learning Group has nothing to disclose.

Millena De Brito, Associate Program Manager for Med Learning Group has nothing to disclose.

Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.